These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
322 related articles for article (PubMed ID: 26774910)
61. Dry eye disease: pathophysiology, classification, and diagnosis. Perry HD Am J Manag Care; 2008 Apr; 14(3 Suppl):S79-87. PubMed ID: 18452371 [TBL] [Abstract][Full Text] [Related]
62. Correlation between tear film osmolarity, dry eye disease, and rheumatoid arthritis. Schargus M; Wolf F; Tony HP; Meyer-Ter-Vehn T; Geerling G Cornea; 2014 Dec; 33(12):1257-61. PubMed ID: 25255140 [TBL] [Abstract][Full Text] [Related]
63. Recent advances in drug treatments for dry eye disease. Coco G; Ambrosini G; Poletti S; Meliante LA; Taloni A; Scorcia V; Giannaccare G Expert Opin Pharmacother; 2023; 24(18):2059-2079. PubMed ID: 37804227 [TBL] [Abstract][Full Text] [Related]
64. Proteases and Their Potential Role as Biomarkers and Drug Targets in Dry Eye Disease and Ocular Surface Dysfunction. Ramos-Llorca A; Scarpellini C; Augustyns K Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077189 [TBL] [Abstract][Full Text] [Related]
65. Importance of tear film instability in dry eye disease in office workers using visual display terminals: the Osaka study. Yokoi N; Uchino M; Uchino Y; Dogru M; Kawashima M; Komuro A; Sonomura Y; Kato H; Tsubota K; Kinoshita S Am J Ophthalmol; 2015 Apr; 159(4):748-54. PubMed ID: 25555800 [TBL] [Abstract][Full Text] [Related]
66. Therapeutic inhibitors for the treatment of dry eye syndrome. Rodríguez-Pomar C; Pintor J; Colligris B; Carracedo G Expert Opin Pharmacother; 2017 Dec; 18(17):1855-1865. PubMed ID: 29115899 [TBL] [Abstract][Full Text] [Related]
67. Rasch analysis of three dry eye questionnaires and correlates with objective clinical tests. McAlinden C; Gao R; Wang Q; Zhu S; Yang J; Yu A; Bron AJ; Huang J Ocul Surf; 2017 Apr; 15(2):202-210. PubMed ID: 28179131 [TBL] [Abstract][Full Text] [Related]
69. TFOS DEWS II Introduction. Nelson JD; Craig JP; Akpek EK; Azar DT; Belmonte C; Bron AJ; Clayton JA; Dogru M; Dua HS; Foulks GN; Gomes JAP; Hammitt KM; Holopainen J; Jones L; Joo CK; Liu Z; Nichols JJ; Nichols KK; Novack GD; Sangwan V; Stapleton F; Tomlinson A; Tsubota K; Willcox MDP; Wolffsohn JS; Sullivan DA Ocul Surf; 2017 Jul; 15(3):269-275. PubMed ID: 28736334 [No Abstract] [Full Text] [Related]
70. Tear osmolarity as a biomarker for dry eye disease severity. Suzuki M; Massingale ML; Ye F; Godbold J; Elfassy T; Vallabhajosyula M; Asbell PA Invest Ophthalmol Vis Sci; 2010 Sep; 51(9):4557-61. PubMed ID: 20393114 [TBL] [Abstract][Full Text] [Related]
71. Automated Tear Film Surface Quality Breakup Time as a Novel Clinical Marker for Tear Hyperosmolarity in Dry Eye Disease. Downie LE Invest Ophthalmol Vis Sci; 2015 Nov; 56(12):7260-8. PubMed ID: 26544794 [TBL] [Abstract][Full Text] [Related]